- Home
- STKS vs CGEN Comparison
STKS vs CGEN Comparison
Compare STKS & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- CGEN
- Stock Information
- Founded
- STKS 2004
- CGEN 1993
- Country
- STKS United States
- CGEN Israel
- Employees
- STKS N/A
- CGEN N/A
- Industry
- STKS Restaurants
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STKS Consumer Discretionary
- CGEN Health Care
- Exchange
- STKS Nasdaq
- CGEN Nasdaq
- Market Cap
- STKS 109.7M
- CGEN 167.4M
- IPO Year
- STKS N/A
- CGEN 2000
- Fundamental
- Price
- STKS $3.33
- CGEN $1.53
- Analyst Decision
- STKS Hold
- CGEN
- Analyst Count
- STKS 3
- CGEN 0
- Target Price
- STKS $4.83
- CGEN N/A
- AVG Volume (30 Days)
- STKS 340.4K
- CGEN 236.0K
- Earning Date
- STKS 08-05-2025
- CGEN 08-06-2025
- Dividend Yield
- STKS N/A
- CGEN N/A
- EPS Growth
- STKS N/A
- CGEN N/A
- EPS
- STKS N/A
- CGEN N/A
- Revenue
- STKS $799,478,000.00
- CGEN $27,589,000.00
- Revenue This Year
- STKS $26.92
- CGEN N/A
- Revenue Next Year
- STKS $5.39
- CGEN $105.77
- P/E Ratio
- STKS N/A
- CGEN N/A
- Revenue Growth
- STKS 138.50
- CGEN N/A
- 52 Week Low
- STKS $2.37
- CGEN $1.13
- 52 Week High
- STKS $5.42
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- STKS 37.71
- CGEN 41.35
- Support Level
- STKS $3.31
- CGEN $1.49
- Resistance Level
- STKS $4.12
- CGEN $1.64
- Average True Range (ATR)
- STKS 0.32
- CGEN 0.08
- MACD
- STKS -0.14
- CGEN -0.02
- Stochastic Oscillator
- STKS 5.52
- CGEN 25.00
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.